Thermo Fisher Scientific Inc. (TMO) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Thermo Fisher Scientific’s revenue went from $18.3B in fiscal 2016 to $44.6B in fiscal 2025, growth of about 10.4% a year.
Net income in fiscal 2025 was $6.7B, a net margin of 15.0%; the best year in this period was 2021 with $7.7B.
Over the twelve months to September 26, 2026, revenue was $47.4B and net income $7.1B.
Free cash flow was $6.3B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 5% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $47.4B | $44.6B | $42.9B | $42.9B | $44.9B | $39.2B | $32.2B | $25.5B | $24.4B | $20.9B | $18.3B |
| Gross profit | — | — | — | — | — | — | — | — | — | $11.9B | $10.1B |
| Operating income | $8.5B | $7.7B | $7.3B | $6.9B | $8.4B | $10.0B | $7.8B | $4.6B | $3.8B | $3.0B | $2.5B |
| Net income | $7.1B | $6.7B | $6.3B | $6.0B | $7.0B | $7.7B | $6.4B | $3.7B | $2.9B | $2.2B | $2.0B |
| EPS (diluted) | $18.96 | $17.74 | $16.53 | $15.45 | $17.63 | $19.46 | $15.96 | $9.17 | $7.24 | $5.59 | $5.09 |
| R&D | $1.4B | $1.4B | $1.4B | $1.3B | $1.5B | $1.4B | $1.2B | $1.0B | $967M | $887M | $754M |
| Revenue growth | — | +3.9% | +0.1% | −4.6% | +14.5% | +21.7% | +26.1% | +4.9% | +16.4% | +14.5% | +7.7% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $9.3B | $7.8B | $8.7B | $8.4B | $9.2B | $9.3B | $8.3B | $5.0B | $4.5B | $4.0B | $3.3B |
| Capital spending | -$1.7B | -$1.5B | -$1.4B | -$1.5B | -$2.2B | -$2.5B | -$1.5B | -$926M | -$758M | -$508M | -$444M |
| Free cash flow | $7.6B | $6.3B | $7.3B | $6.9B | $6.9B | $6.8B | $6.8B | $4.0B | $3.8B | $3.5B | $2.8B |
| Dividends paid | $673M | $636M | $583M | $523M | $455M | $395M | $337M | $297M | $266M | $237M | $238M |
| Buybacks | $4.0B | $3.0B | $4.0B | $3.0B | $3.0B | $2.0B | $1.5B | $1.5B | $500M | $750M | $1.2B |
| Stock-based pay | $345M | $310M | $301M | $278M | $307M | $230M | $196M | $181M | $181M | $159M | $133M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $10.1B | $5.6B | $8.1B | $8.5B | $4.5B | $10.3B | $2.4B | $2.1B | $1.3B | $786M |
| Debt | — | $40.9B | $32.8B | $36.4B | $36.1B | $36.3B | $22.5B | $18.5B | $19.0B | $21.2B | $16.7B |
| Equity | — | $53.4B | $49.6B | $46.7B | $44.0B | $40.8B | $34.5B | $29.7B | $27.6B | $25.4B | $21.5B |
| Total assets | — | $110.3B | $97.3B | $98.7B | $97.2B | $95.1B | $69.1B | $58.4B | $56.2B | $56.7B | $45.9B |
| Shares (diluted) | 371M | 378M | 383M | 388M | 394M | 397M | 399M | 403M | 406M | 398M | 397M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | 57.1% | 55.0% |
| Operating margin | 17.9% | 17.4% | 17.1% | 16.0% | 18.7% | 25.6% | 24.2% | 18.0% | 15.5% | 14.1% | 13.5% |
| Net margin | 14.9% | 15.0% | 14.8% | 14.0% | 15.5% | 19.7% | 19.8% | 14.5% | 12.1% | 10.6% | 11.1% |
| FCF margin | 16.0% | 14.1% | 17.0% | 16.2% | 15.4% | 17.3% | 21.1% | 15.8% | 15.5% | 16.7% | 15.4% |
| ROIC | — | 7.6% | 8.1% | 7.9% | 9.5% | 11.4% | 12.0% | 8.7% | 7.3% | 5.8% | 5.1% |
| ROE | — | 12.6% | 12.8% | 12.8% | 15.8% | 18.9% | 18.5% | 12.4% | 10.7% | 8.8% | 9.4% |
Frequently asked questions
What is Thermo Fisher Scientific’s annual revenue?
$44.6B in fiscal 2025 and $47.4B over the twelve months to September 26, 2026.
How much profit does Thermo Fisher Scientific make?
Net income was $6.7B in fiscal 2025 (net margin 15.0%).
Is Thermo Fisher Scientific’s revenue growing?
Yes: revenue rose 3.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.